Clarion and MassBio Co-Host Forum on NASH
On February 1st, 2018, Clarion and MassBio co-hosted a forum entitled “NASH: A Silent Epidemic Poised to Swamp the BioPharma Industry?” MassBio is a high profile Boston-based group that is at the center of biopharma organizing, educating. and policy setting. The event was envisioned and facilitated by Clarion’s own medical director, Dr. Amama Sadiq. The panel featured three esteemed non-alcoholic steatohepatitis (NASH) thought-leaders, blending medical, commercial, and health economics perspectives: Dr Raza Malik, MD, PhD; Rosana Kapeller, MD, PhD; and Jagpreet Chhatwal, PhD.
The forum attracted 90+ registrants from academia, biopharma, biotech, and VC, including Clarion clients and alumni. The strong interest in the topic comes as no surprise—as a complicated and essential public health issue, NASH is currently in the cross-hairs of industry and the venture investment community. The disorder is highly prevalent with dire clinical consequences and no approved therapies. Triggered by a surge in obesity and metabolic risk factors, NASH affects upwards of 10-15 million Americans and (along with its precursor form NAFLD) is estimated to cost the U.S. more than $100B annually.
The event was a great success – panelists and audience engaged in a dynamic and probing discussion that explored a broad range of topics. Click here to see a brief video highlighting key takeaways from the event, including perspectives on critical aspects of NASH as a disease and potential challenges associated with development in this space.
In addition to providing a platform for the rich exchange of ideas, the event also served to facilitate networking and connections across many of the participants. We at Clarion are proud to be making contributions to meaningful dialog in life sciences for the benefit of patients and our clients.